<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681379</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0114</org_study_id>
    <nct_id>NCT03681379</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Levosimendan in Pediatric Intensive Care Units</brief_title>
  <acronym>PALMAréa</acronym>
  <official_title>Pharmacokinetics of Levosimendan, OR1855 and OR1896 in Neonates and Children With or Without Extracorporeal Membrane Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe pharmacokinetics of levosimendan in neonates and children supported or not with
      extracorporeal circulation devices (ECMO, CRRT)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levosimendan is a calcium sensitiver wih inotropic effects. It's use in the context of acute
      or chronic heart failure in children has yet to be defined. Due to physical proprieties of
      levosimendan and metabolites, we hypothesized that concomitant use of extracorporeal devices
      such as ECMO will cause major pharmacokinetic variations. Furthermore, pharmacokinetics of
      levosimendan in children with multiple organ failure has to be specify.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>First parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (Area under the plasma concentration versus time curve (AUC) )</measure>
    <time_frame>At the end of the study, after 2 years.</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC) of levosimendan, OR 1855 and OR 1896. Samples will be collected over a period in of 192h in context of routine care</description>
  </primary_outcome>
  <primary_outcome>
    <measure>second parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (distribution volume)</measure>
    <time_frame>At the end of the study, after 2 years.</time_frame>
    <description>distribution volume of levosimendan, OR 1855 and OR 1896. Samples will be collected over a period in of 192h in context of routine care</description>
  </primary_outcome>
  <primary_outcome>
    <measure>third parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (half-life time)</measure>
    <time_frame>At the end of the study, after 2 years.</time_frame>
    <description>half-life time of levosimendan, OR 1855 and OR 1896. Samples will be collected over a period in of 192h in context of routine care</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fourth parameter of the pharmacokinetics of levosimendan, OR1855, OR1896 (Peak Plasma Concentration (Cmax))</measure>
    <time_frame>At the end of the study, after 2 years.</time_frame>
    <description>Peak Plasma Concentration (Cmax) of levosimendan, OR 1855 and OR 1896. Samples will be collected over a period in of 192h in context of routine care</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Heart Failure</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients with acute circulatory insufficiency are equipped with a central venous line or
      catheterization for hemodynamic monitoring and biological assessment in context of routine
      care. There will be no specific interventions to the study participants like additional
      venipuncture for this study. The volume required for the analyzes (0.5 ml, 13 times over a
      period of 8 days) are issue from hemodynamic monitoring and biological assessment in context
      of routine care . This volume is compatible with the current french regulation on non
      interventional research.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        children admitted in pediatric intensive care units for acute heart failure
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All children admitted in pediatric intensive care units with planned infusion of 0.2
             mcg/kg/min of levosimendan over 24h in context of routine care

          -  Arterial line or central venous catheter inserted for blood sampling procedures in
             context of routine care.

        Exclusion Criteria:

          -  Absence of clear parental status or information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther. 2002 Oct;40(10):465-71.</citation>
    <PMID>12395979</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>September 21, 2018</last_update_submitted>
  <last_update_submitted_qc>September 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Levosimendan</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>children</keyword>
  <keyword>acute heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

